ATE327735T1 - Taxan-mikroemulsionen - Google Patents

Taxan-mikroemulsionen

Info

Publication number
ATE327735T1
ATE327735T1 AT99915190T AT99915190T ATE327735T1 AT E327735 T1 ATE327735 T1 AT E327735T1 AT 99915190 T AT99915190 T AT 99915190T AT 99915190 T AT99915190 T AT 99915190T AT E327735 T1 ATE327735 T1 AT E327735T1
Authority
AT
Austria
Prior art keywords
taxan
microemulsions
paclitaxel
formulated
dosage forms
Prior art date
Application number
AT99915190T
Other languages
English (en)
Inventor
Indu Parikh
Iskandar Moussa
Alain Carrier
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of ATE327735T1 publication Critical patent/ATE327735T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99915190T 1998-04-01 1999-03-30 Taxan-mikroemulsionen ATE327735T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8027398P 1998-04-01 1998-04-01
US8027298P 1998-04-01 1998-04-01

Publications (1)

Publication Number Publication Date
ATE327735T1 true ATE327735T1 (de) 2006-06-15

Family

ID=26763305

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99915190T ATE327735T1 (de) 1998-04-01 1999-03-30 Taxan-mikroemulsionen

Country Status (12)

Country Link
EP (1) EP1067908B9 (de)
JP (1) JP4695260B2 (de)
KR (1) KR100661879B1 (de)
CN (1) CN100341485C (de)
AT (1) ATE327735T1 (de)
AU (1) AU756752B2 (de)
CA (1) CA2326485C (de)
DE (1) DE69931617T2 (de)
IL (2) IL138767A0 (de)
SE (1) SE0003449L (de)
TW (1) TW546152B (de)
WO (1) WO1999049848A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1998053811A1 (en) * 1997-05-27 1998-12-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
EP1479382A1 (de) * 1999-06-18 2004-11-24 IVAX Research, Inc. Taxane enthaltende orale Pharmazeutische Zusammensetzungen sowie Behandlungsverfahren unter deren Verwendung
AU2006201100B2 (en) * 1999-09-21 2009-09-24 Jagotec Ag Surface modified particulate compositions of biologically active substances
JP2003509453A (ja) * 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
AU7638200A (en) * 1999-10-20 2001-04-30 Vesifact Ag Microemulsion preconcentrates which contain cyclosporines and corresponding microemulsions
MXPA02004164A (es) * 1999-10-27 2002-10-17 Baker Norton Pharma Metodo y composiciones para administrar taxanos por via oral a pacientes humanos.
EP1118333A1 (de) * 2000-01-18 2001-07-25 Eurand International S.P.A. Zusammensetzungen mit erhöhter oraler Bioverfügbarkeit
DE10030378A1 (de) * 2000-06-21 2002-03-14 Audit Inst For Medical Service Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
DE60109295T2 (de) * 2000-07-24 2006-04-13 Sugen, Inc., South San Francisco Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln
EP1337273A2 (de) 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen enthaltend paclitaxel, dessen derivate und dessen pharmazeutisch denkbare saltze
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
DE50101395D1 (de) * 2001-04-12 2004-03-04 Vesifact Ag Baar Pharmazeutische Formulierungen enthaltend entzündungshemmende Wirkstoffe und deren Verwendung
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
DE60231549D1 (de) * 2001-12-03 2009-04-23 Dor Biopharma Inc Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
JP4526120B2 (ja) * 2002-05-22 2010-08-18 日本製薬株式会社 Ｌ−メントール水中油型乳剤
KR20040008816A (ko) * 2002-07-19 2004-01-31 한미약품 주식회사 파클리탁셀 또는 그의 유도체와 ｐ-당단백질 저해제를함유하는 혈관재협착 방지를 위한 경구투여용 약학 조성물
KR100573289B1 (ko) * 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
DE10247399A1 (de) * 2002-10-08 2004-04-29 Schering Ag Pharmazeutische Zubereitungen, Verwendung dieser Zubereitung und Verfahren zur Erhöhung der Bioverfügbarkeit von peroral zu applizierenden Arzneistoffen
EP1498120A1 (de) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Halbfeste Formulierung für die orale Verabreichung des Taxols
EP1498143A1 (de) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Selbstemulgierende und selbstmicroemulgierende Formulierungen zur oralen Verabreichung von Taxoiden
WO2005037250A1 (en) * 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self emulsifying drug delivery systems for hydrophobic therapeutic compounds
WO2005037251A1 (en) * 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self-emulsifying drug delivery systems for hydrophobic therapeutic compounds
CA2556185C (en) * 2004-02-13 2010-09-21 Bioavailability, Inc. A microemulsion preparation of high concentration propofol for anesthetic uses
WO2005089716A1 (ja) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited 高含量化製剤
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
CN100361656C (zh) 2004-08-27 2008-01-16 石药集团中奇制药技术（石家庄）有限公司 丁苯酞自乳化释药体系及其制备方法和应用
HUE029192T2 (en) 2005-03-21 2017-02-28 Teva Czech Ind S R O Anti-crystallization and its use in gelatin capsules
WO2008058366A1 (en) * 2006-09-28 2008-05-22 Université de Montréal Oil-in-water emulsions, methods of use thereof, methods of preparation thereof and kits thereof
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
EP2204167A1 (de) 2009-01-05 2010-07-07 Azad Pharma AG Pharmazeutische Mikroemulsion zur Prävention von supramolekularer Aggregation von ampiphilen Molekülen
CN101785757B (zh) * 2009-01-22 2012-02-22 美迪思生物科技(北京)有限公司 一种紫杉醇自乳化制剂及其制备方法和用途
EP2301523A1 (de) 2009-09-22 2011-03-30 Dr. August Wolff GmbH & Co. KG Arzneimittel Galenische Formulierung in kolloidaler Form
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011038068A1 (en) 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes
CN102228431A (zh) * 2010-03-16 2011-11-02 王国强 紫杉烷类化合物的自乳化药物组合物
JP5824511B2 (ja) * 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
US20120095098A1 (en) * 2010-10-18 2012-04-19 Bhiku Patel Bioavailability Enhancement Delivery System
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2878311A1 (de) * 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Verbesserung der Löslichkeit für hydrophobe Wirkstoffe
EP3086777A1 (de) * 2013-12-23 2016-11-02 Johnson & Johnson Consumer Inc. Racecadotrilzusammensetzungen
DE102014015625A1 (de) 2014-10-16 2016-04-21 Gonzalo Urrutia Desmaison Lösungsvermittelnde Zusammenssetzungen
KR101542364B1 (ko) * 2014-10-31 2015-08-07 대화제약 주식회사 탁산을 포함하는 경구 투여용 약학 조성물
US10987335B2 (en) * 2015-07-30 2021-04-27 Dae Hwa Pharma. Co., Ltd. Pharmaceutical composition for oral administration comprising high concentration taxane
TWI715636B (zh) 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN109589305B (zh) * 2018-12-03 2021-03-19 昆明积大制药股份有限公司 多西他赛-环孢素a共包载自乳化制剂及其制备方法
JP7219344B2 (ja) * 2019-01-07 2023-02-07 プサン ナショナル ユニバーシティ インダストリー－ユニバーシティ コーポレーション ファウンデーション 血液脳関門の透過性を増進させるｗ／ｏ／ｗ型トリオレインエマルジョンを利用した薬物伝達プラットホーム
PL241264B1 (pl) * 2020-02-19 2022-08-29 Inventionbio Spółka Akcyjna Samoemulsyfikująca kompozycja, przeznaczona do podawania naskórnego, zawierająca biosurfaktant, ko-surfaktant oraz fazę olejową

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680441B2 (en) * 1992-09-22 1997-07-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Use of taxol for treating lymphomas and breast cancer
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
GB9509321D0 (en) * 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
TW527186B (en) * 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6060518A (en) * 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
EP1007029A4 (de) * 1997-03-27 2003-03-26 Baker Norton Pharma Verfahren und zusammensetzungen zur behandlung von ovarialkrebs

Also Published As

Publication number Publication date
IL138767A (en) 2007-06-03
AU756752B2 (en) 2003-01-23
CA2326485A1 (en) 1999-10-07
TW546152B (en) 2003-08-11
EP1067908B9 (de) 2007-01-24
JP4695260B2 (ja) 2011-06-08
SE0003449L (sv) 2000-11-23
WO1999049848A1 (en) 1999-10-07
KR20010034622A (ko) 2001-04-25
DE69931617D1 (de) 2006-07-06
SE0003449D0 (sv) 2000-09-27
DE69931617T2 (de) 2007-05-24
KR100661879B1 (ko) 2006-12-27
CA2326485C (en) 2008-12-09
AU3377099A (en) 1999-10-18
IL138767A0 (en) 2001-10-31
CN100341485C (zh) 2007-10-10
EP1067908A1 (de) 2001-01-17
CN1303269A (zh) 2001-07-11
EP1067908B1 (de) 2006-05-31
JP2002509877A (ja) 2002-04-02

Similar Documents

Publication Publication Date Title
DE69931617D1 (de) Taxan-mikroemulsionen
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
MXPA03007712A (es) Sales farmaceuticas.
IT1318539B1 (it) Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
DK1303261T3 (da) Selv-emulgerende lægemiddelafgivelsessystemer til ekstremt vanduoplöselige, lipofile lægemidler
IL128801A (en) Pharmaceutical composition comprising a substance inhibiting no synthase
DE60019167D1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
ATE232100T1 (de) Gegen magensaft geschützte omeprazol- mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ATE292453T1 (de) Antivirale arznei
WO2005007137A8 (de) Ambroxolhaltige tabletten
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
UY28175A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
NO20020572L (no) Flytende farmasöytisk sammensetning som omfatter en aktiv fase og en ikke-aktiv fase
ATE286894T1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
MY141008A (en) Oral formulations of deoxypeganine and their uses
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
ATE347886T1 (de) Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
SE0203817D0 (sv) New composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties